Home Cart 0 Sign in  
X

[ CAS No. 3430-13-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 3430-13-5
Chemical Structure| 3430-13-5
Chemical Structure| 3430-13-5
Structure of 3430-13-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 3430-13-5 ]

Related Doc. of [ 3430-13-5 ]

Alternatived Products of [ 3430-13-5 ]

Product Details of [ 3430-13-5 ]

CAS No. :3430-13-5 MDL No. :MFCD00661170
Formula : C6H6BrN Boiling Point : -
Linear Structure Formula :- InChI Key :OFKWIQJLYCKDNY-UHFFFAOYSA-N
M.W : 172.02 Pubchem ID :1201020
Synonyms :

Calculated chemistry of [ 3430-13-5 ]

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.17
Num. rotatable bonds : 0
Num. H-bond acceptors : 1.0
Num. H-bond donors : 0.0
Molar Refractivity : 36.9
TPSA : 12.89 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.04 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.94
Log Po/w (XLOGP3) : 1.85
Log Po/w (WLOGP) : 2.15
Log Po/w (MLOGP) : 1.58
Log Po/w (SILICOS-IT) : 2.54
Consensus Log Po/w : 2.01

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.63
Solubility : 0.406 mg/ml ; 0.00236 mol/l
Class : Soluble
Log S (Ali) : -1.74
Solubility : 3.12 mg/ml ; 0.0181 mol/l
Class : Very soluble
Log S (SILICOS-IT) : -3.26
Solubility : 0.0948 mg/ml ; 0.000551 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.22

Safety of [ 3430-13-5 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 3430-13-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 3430-13-5 ]
  • Downstream synthetic route of [ 3430-13-5 ]

[ 3430-13-5 ] Synthesis Path-Upstream   1~35

  • 1
  • [ 3222-48-8 ]
  • [ 3430-13-5 ]
Reference: [1] Patent: WO2012/101453, 2012, A1, . Location in patent: Page/Page column 47
  • 2
  • [ 109-06-8 ]
  • [ 3430-13-5 ]
  • [ 38749-79-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1987, vol. 30, # 5, p. 871 - 880
[2] Journal of Labelled Compounds and Radiopharmaceuticals, 2006, vol. 49, # 9, p. 789 - 799
  • 3
  • [ 109-06-8 ]
  • [ 3430-13-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 4, p. 1992 - 2010
[2] Polyhedron, 2010, vol. 29, # 7, p. 1854 - 1862
  • 4
  • [ 14401-91-3 ]
  • [ 3430-13-5 ]
Reference: [1] Journal of the American Chemical Society, 1943, vol. 65, p. 2233,2235
  • 5
  • [ 1121-78-4 ]
  • [ 3430-13-5 ]
Reference: [1] Patent: EP1422218, 2004, A1, . Location in patent: Page 162
  • 6
  • [ 21684-59-3 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
[2] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 7
  • [ 80287-53-2 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 8
  • [ 6960-22-1 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 9
  • [ 197079-25-7 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 10
  • [ 64038-04-6 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 11
  • [ 247077-42-5 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 12
  • [ 858844-85-6 ]
  • [ 3430-13-5 ]
Reference: [1] Journal fuer Praktische Chemie (Leipzig), 1932, vol. <2> 133, p. 36,49
  • 13
  • [ 3430-13-5 ]
  • [ 695-17-0 ]
Reference: [1] Tetrahedron Letters, 2006, vol. 47, # 12, p. 1877 - 1879
  • 14
  • [ 3430-13-5 ]
  • [ 68-12-2 ]
  • [ 4985-92-6 ]
YieldReaction ConditionsOperation in experiment
45%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 0.5 h;
Stage #2: for 0.5 h;
Intermediate 161 : 5-methyl-2-pyridinecarbaldehvde; 5 g of 5-bromo-2-methylpyridine (29.1 mmole, Aldrich), dissolved in 60 mL of dry THF.The solution was cooled to -780C. To this solution, were added 15.99 mL of BuLi (32.0 mmole) and the reaction mixture was stirred at -780C for 0.5 h. Then 4.50 mL of dry DMF <n="175"/>(58.1 mmole) were added and stirring was continued for 0.5 h. 30 mL of water were added followed by 100 mL of AcOEt. The organic layer was separated, dried over Na2SO4, filtered and evaporated under vacuum to give a crude that was purified on Isco- Companion (CH/AcOEt 1 :1 to 1 :9) to give the title compound as a yellow oil (1.6 g, 45percent yield). 1H-NMR (400 MHz, CDCI3): δ 1.99 (s, 3H), 7.22 (d, 1 H), 7.43 (d, 1 H), 8.16 (s, 1 H), 9.59 (s, 1 H); m/z (ES): 121.99 [M+H]+.
Reference: [1] Patent: WO2008/148853, 2008, A1, . Location in patent: Page/Page column 172-173
  • 15
  • [ 3430-13-5 ]
  • [ 68-12-2 ]
  • [ 53014-84-9 ]
YieldReaction ConditionsOperation in experiment
72%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 1 h;
Stage #2: at -78℃; for 1 h;
To a solution of 5-bromo-2-methylpyridine (151; 10 g, 58.1 mmol) in THF (150 mL) was added n-BuLi (2.5 M, 25.6 mL) at -78 0C. The reaction mixture was stirred at this temperature for Ih. DMF (1.30 mL) was then added and the resulting reaction mixture was stirred for 1 h at -78 °C. The reaction was quenched by the addition of aq. NH4Cl. Upon warming to room temperature, the mixture was extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure. The resulting residue was purified by chromatography to afford 6-methylnicotinaldehyde 152 (5.0 g, 72percent).
72%
Stage #1: With n-butyllithium In tetrahydrofuran at -78℃; for 1 h;
Stage #2: at -78℃; for 1 h;
Example 22. Synthesis of 2-(6-methylpyridin-3-yl)-N-(thiazol-2-yl)-[l,2,4]triazolo[l,5- a]pyridine-8-carboxamide (Compound 210): Step 1) Preparation of 6-methylnicotinaldehyde (93): 91To a solution of 5-bromo-2-methylpyridine (91; 10 g, 58.1 mmol) in THF (150 mL) was added n-BuLi (2.5 M, 25.6 mL) at -78 0C. The reaction mixture was stirred at this temperature for Ih. DMF (1.30 mL) was then added and the resulting reaction mixture was stirred for 1 h at -78 0C. The reaction was quenched by the addition of aq. NH4Cl. Upon warming to room temperature, the mixture was extracted with EtOAc. The combined organic layers were dried (Na2SO4) and concentrated under reduced pressure. The resulting residue was purified by chromatography to afford 6-methylnicotinaldehyde 92 (5.0 g, 72percent).
38%
Stage #1: With n-butyllithium; isopropylmagnesium chloride In tetrahydrofuran; hexane at 10℃; for 1 h;
Stage #2: at 20℃; for 2 h;
Step 1
6-Methylnicotinaldehyde:
At about 0° C. and under an atmosphere of nitrogen, n-butyllithium (2.5 M in hexane, 20 mL, 1.00 equiv) was added to a solution of isopropylmagnesiumchloride (2.0 M in tetrahydrofuran, 12.5 mL, 0.50 equiv) in tetrahydrofuran (100 mL).
The resulting solution was stirred at about 0° C. for about 30 minutes, and then 5-bromo-2-methylpyridine (8.6 g, 50 mmol, 1.00 equiv) was added.
After stirring for about 1 hour at about -10° C., dimethylformamide (14.6 g, 200 mmol, 4.00 equiv) was added.
The resulting solution was stirred at ambient temperature for about 2 hours, and then saturated ammonium chloride was added.
Following standard extractive workup with ethyl acetate (3*50 mL), the crude residue was purified by silica gel column chromotagraphy (ethyl acetate/petroleum ether (1:2)) to give the title product as a light yellow oil (2.3 g; yield=38percent). LC-MS: m/z=122 (MH)+.
4.5 g
Stage #1: With isopropylmagnesium chloride In tetrahydrofuran at 0 - 20℃; for 6 h;
Stage #2: at 0 - 20℃;
To a solution of 5-bromo-2-methyl-pyridine (2.0 g, 11.6mmol) in anhydrous THF (20 mL) was added isopropylmagnesium chloride (2M in THF, 9.3 mL, 1.6 eq). dropwise over 30 mins at 0 °C under nitrogen atmosphere, then the reaction mixture was stirred at room temperature for 6 hrs. DMF (1.02 g, 1.2 eq) was added to the reation mixture at 0 °C for 30 mi amd the mixture was the stirred at room temperature for overnight. The reaction mixture was poured into water (50 mL), and the aqueous phase was extracted with EtOAc (50 mL x3). The extracts were washed with brine (50 mL), dried over Na2SO4 and concentrated in vacuum to give 4.5 g of crude 6-methylpyridine-3-carbaldehyde as yellow oil.

Reference: [1] Tetrahedron Letters, 2006, vol. 47, # 12, p. 1877 - 1879
[2] Patent: WO2010/3048, 2010, A1, . Location in patent: Page/Page column 130-131
[3] Patent: WO2009/146358, 2009, A1, . Location in patent: Page/Page column 97
[4] Patent: US2010/125085, 2010, A1, . Location in patent: Page/Page column 16
[5] Patent: WO2016/123392, 2016, A2, . Location in patent: Paragraph 00595
  • 16
  • [ 3430-13-5 ]
  • [ 13411-48-8 ]
  • [ 36357-38-7 ]
Reference: [1] Organic Letters, 2014, vol. 16, # 3, p. 824 - 827
  • 17
  • [ 3430-13-5 ]
  • [ 100189-17-1 ]
Reference: [1] Patent: WO2014/198808, 2014, A1,
[2] Patent: EP2813505, 2014, A1,
  • 18
  • [ 3430-13-5 ]
  • [ 30766-11-1 ]
YieldReaction ConditionsOperation in experiment
39% With potassium permanganate In water at 80℃; 4.1.7
5-Bromopyridine-2-carboxylic acid (11)
In a 250 mL three-necked flask equipped with a stirrer, a thermometer, and a condenser, 150 mL water and 5-bromo-2-methylpyridine (10) (6.0 g, 35 mmol) was added to it and stirring until the temperature was raised to 80 °C, then KMnO4 (24.8 g, 157 mmol) was added in three batches at intervals of 1 h.
The mixture was stirred at the same temperature for 3-4 h.
After completion of the reaction, suction filtration to give a clear solution, the solution was adjusted to pH 4-5 with concentrated HCl, some white solid precipitated, the filter cake is a small amount of the product (11), after filtration and concentration in vacuo, an appropriate amount of ethanol was added to the residues to dissolve the residue compound (11), a lot of white solid precipitated, discarded it after subjected to suction filtration again, finally the filtrate was concentrated in vacuo, total yielding (11) (3.0 g, 39percent) as light yellow solid.
Reference: [1] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 13, p. 3228 - 3236
[2] Journal fuer Praktische Chemie (Leipzig), 1932, vol. &lt;2&gt; 133, p. 36,49
[3] Heterocycles, 1981, vol. 15, # 1, p. 213 - 223
[4] Synthesis, 2003, # 4, p. 551 - 554
[5] Patent: US2005/113374, 2005, A1, . Location in patent: Page/Page column 8
  • 19
  • [ 3430-13-5 ]
  • [ 19733-96-1 ]
Reference: [1] Patent: WO2014/198808, 2014, A1,
[2] Patent: EP2813505, 2014, A1,
  • 20
  • [ 109-06-8 ]
  • [ 3430-13-5 ]
  • [ 38749-79-0 ]
Reference: [1] Journal of Medicinal Chemistry, 1987, vol. 30, # 5, p. 871 - 880
[2] Journal of Labelled Compounds and Radiopharmaceuticals, 2006, vol. 49, # 9, p. 789 - 799
  • 21
  • [ 3430-13-5 ]
  • [ 31181-90-5 ]
Reference: [1] Tetrahedron Letters, 2005, vol. 46, # 36, p. 6033 - 6036
[2] Patent: WO2008/91681, 2008, A2, . Location in patent: Page/Page column 205-206
[3] Patent: WO2008/91681, 2008, A2, . Location in patent: Page/Page column 231
[4] Patent: US2010/16298, 2010, A1, . Location in patent: Page/Page column 173
  • 22
  • [ 3430-13-5 ]
  • [ 88139-91-7 ]
YieldReaction ConditionsOperation in experiment
78%
Stage #1: With 3-chloro-benzenecarboperoxoic acid In dichloromethane for 2 h;
Part A: Compound 413 (3.5 g, 20.7 mmol) was dissolved in methylene chloride (100 ml) and m-CPBA (4.95 g, 28.9 mmol) was added. The reaction mixture was stirred for two hours and then quenched with saturated sodium carbonate and stirred overnight. The organic layer was dried over sodium sulfate and the concentrated to provide a yellow solid (3.8 g). The solid was placed under argon and trifluoroacetic anhydride (15 mL) was added slowly. The reaction was stirred for 30 minutes at room temperature and then refluxed for 30 minutes. The reaction was cooled to room temperature and quenched slowly with saturated sodium bicarbonate. Methylene chloride was added and the organic layer was washed dried over sodium sulfate and concentrated. Column chromatography (2 to 1 ethyl acetate/hexanes) provided the desired product (3.O g, 78percent).1H NMR (400 MHz, CDCI3) δ 8.65 (d, 1H), 7.8 (m, 1H), 7.2 (d, 1H), 4.7 (s, 2H).
Reference: [1] Patent: WO2007/84451, 2007, A1, . Location in patent: Page/Page column 146
[2] Journal of Medicinal Chemistry, 1987, vol. 30, # 5, p. 871 - 880
[3] Polyhedron, 2010, vol. 29, # 7, p. 1854 - 1862
[4] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4721 - 4734
  • 23
  • [ 3430-13-5 ]
  • [ 77199-09-8 ]
Reference: [1] Heterocycles, 1981, vol. 15, # 1, p. 213 - 223
  • 24
  • [ 3430-13-5 ]
  • [ 4248-19-5 ]
  • [ 323578-37-6 ]
Reference: [1] Tetrahedron Letters, 2010, vol. 51, # 33, p. 4445 - 4448
  • 25
  • [ 3430-13-5 ]
  • [ 168823-76-5 ]
Reference: [1] Journal of Medicinal Chemistry, 2011, vol. 54, # 13, p. 4721 - 4734
[2] Patent: WO2007/84451, 2007, A1,
  • 26
  • [ 3430-13-5 ]
  • [ 659742-21-9 ]
Reference: [1] Patent: US2010/41714, 2010, A1, . Location in patent: Page/Page column 17
[2] British Journal of Pharmacology, 2018, vol. 175, # 17, p. 3470 - 3485
  • 27
  • [ 3430-13-5 ]
  • [ 5419-55-6 ]
  • [ 659742-21-9 ]
Reference: [1] Journal of Materials Chemistry C, 2014, vol. 2, # 29, p. 5793 - 5804
  • 28
  • [ 3430-13-5 ]
  • [ 137178-88-2 ]
Reference: [1] Bioorganic and Medicinal Chemistry, 2015, vol. 23, # 13, p. 3228 - 3236
  • 29
  • [ 3430-13-5 ]
  • [ 768-35-4 ]
  • [ 713143-67-0 ]
Reference: [1] Patent: JP2005/82526, 2005, A, . Location in patent: Page/Page column 25
  • 30
  • [ 3430-13-5 ]
  • [ 79-22-1 ]
  • [ 917023-06-4 ]
Reference: [1] Angewandte Chemie - International Edition, 2015, vol. 54, # 37, p. 10975 - 10979[2] Angew. Chem., 2015, vol. 127, # 37, p. 11126 - 11130,5
  • 31
  • [ 3430-13-5 ]
  • [ 917023-06-4 ]
Reference: [1] Patent: WO2013/43232, 2013, A2,
  • 32
  • [ 3430-13-5 ]
  • [ 1003711-85-0 ]
Reference: [1] Patent: WO2008/124610, 2008, A1,
[2] Patent: WO2008/124614, 2008, A1,
  • 33
  • [ 3430-13-5 ]
  • [ 1060802-25-6 ]
Reference: [1] Patent: WO2008/121786, 2008, A1,
  • 34
  • [ 3430-13-5 ]
  • [ 1428761-14-1 ]
Reference: [1] Patent: WO2013/43232, 2013, A2,
  • 35
  • [ 3430-13-5 ]
  • [ 39971-65-8 ]
  • [ 1211517-98-4 ]
  • [ 1211591-90-0 ]
Reference: [1] Journal of the American Chemical Society, 2013, vol. 135, # 32, p. 12122 - 12134
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 3430-13-5 ]

Bromides

Chemical Structure| 38749-90-5

[ 38749-90-5 ]

5-Bromo-2-ethylpyridine

Similarity: 0.91

Chemical Structure| 27063-90-7

[ 27063-90-7 ]

5-Bromo-2,3-dimethylpyridine

Similarity: 0.89

Chemical Structure| 111770-86-6

[ 111770-86-6 ]

5-Bromo-2-ethynylpyridine

Similarity: 0.87

Chemical Structure| 173999-23-0

[ 173999-23-0 ]

(5-Bromopyridin-2-yl)methanamine

Similarity: 0.87

Chemical Structure| 1251953-03-3

[ 1251953-03-3 ]

(5-Bromopyridin-2-yl)methanamine dihydrochloride

Similarity: 0.85

Related Parent Nucleus of
[ 3430-13-5 ]

Pyridines

Chemical Structure| 38749-90-5

[ 38749-90-5 ]

5-Bromo-2-ethylpyridine

Similarity: 0.91

Chemical Structure| 27063-90-7

[ 27063-90-7 ]

5-Bromo-2,3-dimethylpyridine

Similarity: 0.89

Chemical Structure| 111770-86-6

[ 111770-86-6 ]

5-Bromo-2-ethynylpyridine

Similarity: 0.87

Chemical Structure| 173999-23-0

[ 173999-23-0 ]

(5-Bromopyridin-2-yl)methanamine

Similarity: 0.87

Chemical Structure| 1251953-03-3

[ 1251953-03-3 ]

(5-Bromopyridin-2-yl)methanamine dihydrochloride

Similarity: 0.85